Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Ruszniewski, Philippe; Valle, Juan W.; Lombard‐Bohas, Catherine; Cuthbertson, Daniel J.; Perros, Petros; Holubec, Luboš; Fave, Gianfranco Delle; Smith, Denis; Niccoli, Patricia; Maisonobe, Pascal; Atlan, Philippe; Caplin, Martyn

doi:10.1016/j.dld.2015.12.013

Cited by 45 publications

(49 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a proportion of patients with time, especially patients with F-NETs with nongastrinoma, insulinoma syndromes, treated with somatostatin analogues, develop increasing resistance with time, when used at conventional doses[94–98]. Numerous studies, especially in patients with the carcinoid syndrome or VIPomas, have reported that increasing the doses of the somatostatin analogues by either using a higher dose, or using a conventional dose, at increased frequency than is conventionally used (more frequent than 1x/month) can help control the hormone-excess symptoms[94, 95, •96, 97–102]. …”

Section: Summary Of Recent Advances/controversies In Management Ofmentioning

confidence: 99%

“…Long acting somatostatin analogues(Octreotide-LAR, Lanreotide-autogel) supplemented during break-through with subcutaneous octreotide, are the standard therapies for controlling the principal carcinoid syndrome symptoms of diarrhea, flushing, and asthma[2, •96, 98, •120, 145, •146]. With time, refractory cases may develop and therefore, there is a need for new treatments[2, •96, 98, •120, 145, •146].…”

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

“…With time, refractory cases may develop and therefore, there is a need for new treatments[2, •96, 98, •120, 145, •146]. Treatment of the carcinoid heart disease involves standard treatment for heart failure/arrhymias and in advanced cases, heart valve replacement[147].…”

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

“…Both studies and case reports have reported the successful use in patients with carcinoid syndrome of the control of the symptoms of the hormone-excess state by using: everolimus[•38]; PRRT[•56, 57, 66, 95, •96, •148]; liver-directed therapies including TACE/TAE[70, 72, •73, 77, 95, 98, 149]; radioembolization[70, 150, 151]; RFA[80, 81, 83, 95, 152]; by increasing the dosage of octreotide/Lanreotide in refractory cases[94, 97, 153–155]; use of cytoreductive surgery[23, 95, 156–160]; use of 131 I-MIBG[95, 105, 106, 108, 110, •161, 162–164]; with the use of the tryptophan hydroxylase inhibitor, Telotristat[108, 113, 114, ••116, •117, 118, 119] and with pasireotide in octreotide resistant cases[•122]. …”

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Ito¹,

Lee²,

Jensen³

2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction Neuroendocrine tumors(NETs), once thought rare, are increasing in frequency in most countries and receiving increasing-attention. NETs present two-treatment problems. A proportion is functional, hormone-excess-state(F-NET), each of which must be treated. Recently, there are many advances, well-covered in reviews/consensus papers on imaging-NETs;new, novel anti-tumor treatments and understanding their pathogenesis. However, little attention has been paid to advances in the treatment of the hormone-excess-state. These advances are usually reported in case-series, and case-reports with few large studies. In this paper these advances are reviewed. Areas covered Advances in the last 5-years are concentrated on, but a review up to 10-years was performed. PubMed and other databases(Cochrane, etc) were searched for F-NET-syndromes including carcinoid-syndrome, as well as meeting-abstracts on NETs. All advances that controlled hormone-excess-states or facilitated-control were covered. These include new medical-therapies[serotonin-synthesis inhibitors(telotristat), Pasireotide, new agents for treating ACTHomas], increased dosing with conventional therapies(octreotide-LAR, Lanreotide-Autogel), mTor inhibitors(everolimus), Tyrosine-kinase inhibitors(sunitinib), cytoreductive surgery, liver-directed therapies(embolization, chemoembolization, radioembolization, RFA), peptide radio-receptor-therapy(PRRT) and 131I-MIBG, ablation of primary F-NETs. Expert Opinion Although many of the newer therapies controlling the hormone-excess-states in F-NETs are reported in relatively few patients, all the approaches show promise. Their description also generates some controversies/unresolved areas, such as the order of these new treatments, their longterm-efficacy, and effectiveness of combinations which may require large, controlled studies.

show abstract

Section: Summary Of Recent Advances/controversies In Management Ofmentioning

confidence: 99%

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

Section: Summary Of Recent Advances In Management Of Specific Hormmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Ito¹,

Lee²,

Jensen³

2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…54 Satisfaction with diarrhea control and flushing control and a good impact on the quality of life have also been reported in an open-label observational study (Table 2). 55 Moreover, the once-monthly dosing regimen of LAN is associated with improved patient adherence and patient perception of LAN injection 56,57…”

Section: Use Of Lan Autogel In Gep-nensmentioning

confidence: 99%

Clinical utility of lanreotide Autogel<sup>®</sup> in gastroenteropancreatic neuroendocrine tumors

Paragliola¹,

Prete²,

Papi³

et al. 2016

DDDT

View full text Add to dashboard Cite

Somatostatin analogs (SSAs), which were initially used to control hormonal syndromes associated with neuroendocrine neoplasms (NENs), have been successfully proposed as antiproliferative agents, able to control tumor growth in patients affected by gastroenteropancreatic (GEP)-NENs. The development of long-acting formulations of SSAs which require only weekly or monthly injections can improve patient compliance. In particular, lanreotide (LAN) Autogel®, which is a viscous aqueous formulation supplied in ready-to-use prefilled syringes, can be administered every 28–56 days. Since its introduction in the clinical practice, several studies evaluated the clinical utility of LAN Autogel in the medical treatment of GEP-NENs. Although there is no evidence of an overall survival benefit, these studies confirm the efficacy of LAN Autogel in terms of benefit in progression-free survival, and in more than half of cases, a reduction of tumor markers can be observed during treatment with this drug. Moreover, LAN Autogel is widely recognized to be effective in controlling tumor-related symptoms in the majority of patients affected by GEP tumors, especially in patients affected by carcinoid syndrome, improving considerably patients’ quality of life.

show abstract

Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours

et al. 2021

View full text Add to dashboard Cite

Background and Aims: Diarrhoea is a common and debilitating symptom of Carcinoid syndrome. Effective control of symptoms is achieved with somatostatin analogues (SSAs) and additional loperamide and/or codeine phosphate. Symptom control is lost with time and disease progression. There is, therefore, a strong need for additional and more effective therapies. Telotristat-ethyl is a peripheral tryptophanhydroxylase inhibitor approved for treatment of diarrhoea. Here, we present our experience of Telotristat for treating carcinoid diarrhoea in a large cohort of patients outside of clinical trials. The primary outcome was reduction in stool frequency of >30%, as defined in most studies. Methods: Patients were identified from a prospective database and information collected retrospectively from the hospital's electronic patient records. We included 31 patients (25 males, 6 females; Median age 69 years) on Telotristat and 10 patients on fortnightly high-dose SSA (6 males, 4 females; Median age 67 years). Results: The mean (range) duration of treatment in telotristat and 2 weekly SSA groups was 258 (15-479) and 689 (219-1446) days respectively. Primary endpoint was achieved in 82% (23/28) patients on Telotristat with median percentage reduction in stool frequency of 60% (IQR 50-69), compared to 28% (2/7) (22 (−30 to 55) %) in the control group. Odds ratio for reduction in stool frequency >30% was −11,

show abstract

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Abstract: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).

Cited by 45 publications

References 30 publications

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Clinical utility of lanreotide Autogel<sup>®</sup> in gastroenteropancreatic neuroendocrine tumors

Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours

Contact Info

Product

Resources

About

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

Abstract: Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).

Cited by 45 publications

References 30 publications

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Clinical utility of lanreotide Autogel<sup>&reg;</sup> in gastroenteropancreatic neuroendocrine tumors

Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours

Contact Info

Product

Resources

About

Clinical utility of lanreotide Autogel<sup>®</sup> in gastroenteropancreatic neuroendocrine tumors